Tag:

Crucell

Latest Headlines

Latest Headlines

Crucell wins $70M to develop new vaccines

FierceBiotech | October 3, 2008
Crucell has nailed a $70 million contract from the National Institutes of Allergy and Infectious Diseases to develop new vaccines to combat the Ebola and Marburg viruses. That contract will be worth

Developers tout protein manufacturing breakthrough

FierceBiotech | June 16, 2008
A joint venture between Crucell and DSM Biologics- Percivia-- has produced a new, more efficient approach to manufacturing monoclonal antibodies and proteins. By relying on human cell lines rather

Crucell reports early-stage success with TB vaccine

April 10, 2008
Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. The Dutch biotech is

In surprise move, Crucell dumps West Nile program

FierceBiotech | February 12, 2008
The Dutch developer Crucell has opted to shelve its development program for a West Nile vaccine after seeing a drop in the number of people infected by the virus in the U.S. That was a surprise move

ALSO NOTED: iCardiac gains venture funds; Sirtris reports rising R&D expenses; Nanogen slashes staff; and much more...

FierceBiotech | November 13, 2007
> iCardiac Technologies, which has advanced new technology to assess drug safety, has announced a second round of venture capital but is staying mum about just how much money it is getting.

ALSO NOTED: NicOx posts positive osteoarthritis data; Genzyme snares diagnostics unit; Infinity regains program rights; and muc

FierceBiotech | November 12, 2007
> France's NicOx has posted positive data from a late-stage study of naproxcinod for osteoarthritis.

Sanofi launches trial of revolutionary flu vaccine

FierceBiotech | November 7, 2007
Sanofi-Aventis has launched a mid-stage study of a new seasonal flu vaccine that hopes to advance a completely new method to make vaccines. The vaccine is made from cell cultures as opposed to the

SPOTLIGHT: Crucell, MedImmune strike deal

FierceBiotech | October 15, 2007
Dutch biotech Crucell has inked a joint venture deal with MedImmune to develop its bacterial antibodies to treat hospital-acquired infections. MedImmune has agreed to provide upfront, annual and

ALSO NOTED: Crucell disavows trial failure; Emisphere agrees to $18M settlement; Elusys wins $12M contract; and much more...

FierceBiotech | September 25, 2007
> Crucell says you shouldn't blame its technology for the failure of Merck's

Press Release: Crucell N.V. Announces STAR(TM) Research License Agreement With Novo Nordisk

FierceBiotech | January 16, 2007
Press Release: Crucell N.V. Announces STAR(TM) Research License Agreement With Novo Nordisk
Related Tags

Crucell Press Releases

  • ProFibrix Secures Funding for Progression of Lead Product Into Late Stage Clinical Development and Announces Management and Supe
  • Johnson & Johnson Launches Recommended Public Offer to Acquire Crucell
  • Johnson & Johnson and Crucell Progress Update: Expect to Commence Public Offer Prior to 10 December 2010
  • Watson’s Eden Biodesign and Crucell Sign Vendor Network Agreement Facilitating Access to cGMP Manufacturing Services for V
  • Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer
Press Releases
  • Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries
  • Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum
  • MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics
  • BioMed Realty Trust Signs A New 12-Year Lease Establishing New Innovation And R&D Center In Kendall Square In Cambridge, Massachusetts
  • Catalyst Pharmaceuticals Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
  • More Press Releases
Sponsored Links